Work

Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps9102

Authors: Daniel Morgensztern, Wael A. Harb, Kurt Alex Schalper, Melissa Leigh Price, Brandon Early, Taylor Houghton Schreiber

Institutions: Washington University in St. Louis, Horizon Oncology Center, Yale University, Heat Biologics (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2780265289

Cites:

Cited by: 2

Related to: 10